NDSU and Sanford Health Partner on GLP-1 Research Initiative
NDSU and Sanford Health are launching a research collaboration to evaluate factors that may affect the outcomes of next-generation GLP-1 obesity-management medications. The project is funded by a $210,000 investment from NDSU, Sanford Health and the North Dakota Department of Health and Human Services is designed to foster collaboration among research scientists with diverse expertise and backgrounds across both organizations.
Compounded GLP-1 ban: What providers need to know
In a recent regulatory shift, the FDA has ended the allowance for compounding pharmacies to produce copycat versions of popular GLP-1 receptor agonists. Here’s what you need to know.
PRESCRIBING SEMAGLUTIDE: The Importance of Shared Decision-Making
GLP-1 receptor agonists (GLP-1 RAs), of which semaglutide is an example, have emerged as a prominent therapeutic option for managing type 2 diabetes.